Please Note: At this time only Collaborative Externally Sponsored Research proposals will be considered for T-DXd (except Japan-only studies)

HER2+ Breast Cancer

• Optimal treatment approaches to maximize patient experience and outcomes with T-DXd in 1L mBC and eBC [T-DXd - Breast: 0123]
• Exploration of benefit of T-DXd in broadening the patient population in eBC [T-DXd - Breast: 0124]
• Combination treatment strategies with novel modalities [T-DXd - Breast: 0125]
• Evaluate peri-operative strategies with T-DXd in eBC [T-DXd - Breast: 0126]

HER2low Breast Cancer

• Exploration of benefit of T-DXd in subpopulations with high unmet need [T-DXd - Breast: 0127]
• Clinical applicability of technologies (AI / Digital / Computational path) to approach patient ID, spanning the HER2 spectrum [T-DXd - Breast: 0132]
• Explore approaches to maximize patient response [T-DXd - Breast: 0133]

Breast Indication Non-specific

• Novel combinations, translational or clinical approaches to delay resistance and optimize outcomes [T-DXd - Breast: 0128]
• Characterizing treatment patterns and benefit risk profile in BC using large scale RWE [T-DXd - Breast: 0129]
• Identify population at risk for high-grade AEs and strategies for prophylaxis & management and optimize patient's experience [T-DXd - Breast: 0130]
• Rechallenge strategies with T-DXd within different LoT [T-DXd - Breast: 0131]

HER2-expressing Gastric Cancer

• In early disease: Unmet need, outcomes by geographic location, and HER2 expression
  In advanced disease: Real-world outcomes, treatment patterns and sequencing such as following immuno-oncology and/or other regimens [T-DXd - GI: 0146]
• Clinical activity and safety in HER2-expressing disease, including combinations with T-DXd [T-DXd - GI: 0147]
• HER2 dynamics and prevalence over time in response to different treatment combinations/monotherapy (including overlapping biomarkers) [T-DXd - GI: 0153]

HER2-actionable Non-Small Cell Lung Cancer (NSCLC)

• T-DXd efficacy and safety in 2L+ HER2 IHC 2+ NSCLC [T-DXd - Lung: 0167]
• T-DXd as the backbone for novel combinations in HER2-altered 1L, exploring T-DXd safety and dosing [T-DXd - Lung: 0168]
• T-DXd central nervous system brain metastasis efficacy in HER2 (overexpression, mutant) NSCLC [T-DXd - Lung: 0169]
• Temporal changes in HER2 expression, through paired biopsies, across lines of treatment [T-DXd - Lung: 0170]

HER2-expressing Tumor Agnostic

• Real-world T-DXd efficacy / safety, patient characteristics and biomarker expression in HER2-expressing malignancies with limited data or sub-populations of interest [T-DXd - Tumor Agnostic: 0139]
• Novel technologies and methods to support patient identification [T-DXd - Tumor Agnostic: 0140]
• Companion diagnostics utilization and real-world testing patterns [T-DXd - Tumor Agnostic: 0141]
• Treatment patterns and impact of sequencing of novel treatments on T-DXd efficacy, safety and biomarker expression [T-DXd - Tumor Agnostic: 0142]

HER2-expressing Gynecological Tumors

• Efficacy/safety of T-DXd-based regimens in lower IHC expression levels and rare gynecologic cancer histologies [T-DXd - GYN: 0155]
• HER2 overlap with other biomarkers in gynecologic cancers [T-DXd - GYN: 0156]
• Real-world outcomes of HER2-expressing patient populations in high-risk adjuvant endometrial cancer [T-DXd - GYN: 0158]
• Real-world treatment patterns and outcomes of HER2+ patients in 1L ovarian cancer and relevant stratification with other subpopulations (e.g., BRCA, HRD, HER2 and PARPi/bevacizumab use) [T-DXd - GYN: 0154]

To apply, click here to return to the homepage where you will find detailed instructions on the "How to Apply" tab.

Please make note of the code related to the AOI you will be submitting against – you will need this during the application process.

Note: if a proposal does not fit a listed AOI, please select the one that you consider most relevant. Proposals that align to posted AOIs will be prioritized, but proposals that do not fit the AOIs will still be evaluated based on scientific rigor and strategic interest.